Literature DB >> 20421143

Improved dosimetric and clinical outcomes with intensity-modulated radiotherapy for head-and-neck cancer of unknown primary origin.

Allen M Chen1, Bao-Qing Li, D Gregory Farwell, Joseph Marsano, Srinivasan Vijayakumar, James A Purdy.   

Abstract

PURPOSE: To compare differences in dosimetric, clinical, and quality-of-life endpoints among a cohort of patients treated by intensity-modulated radiotherapy (IMRT) and conventional radiotherapy (CRT) for head-and-neck cancer of unknown primary origin. METHODS AND MATERIALS: The medical records of 51 patients treated by radiation therapy for squamous cell carcinoma of the head and neck presenting as cervical lymph node metastasis of occult primary origin were reviewed. Twenty-four patients (47%) were treated using CRT, and 27 (53%) were treated using IMRT. The proportions of patients receiving concurrent chemotherapy were 54% and 63%, respectively.
RESULTS: The 2-year estimates of overall survival, local-regional control, and disease-specific survival for the entire patient population were 86%, 89%, and 84%, respectively. There were no significant differences in any of these endpoints with respect to radiation therapy technique (p>0.05 for all). Dosimetric analysis revealed that the use of IMRT resulted in significant improvements with respect to mean dose and V30 to the contralateral (spared) parotid gland. In addition, mean doses to the ipsilateral inner and middle ear structures were significantly reduced with IMRT (p<0.05 for all). The incidence of severe xerostomia in the late setting was 58% and 11% among patients treated by CRT and IMRT, respectively (p<0.001). The percentages of patients who were G-tube dependent at 6 months after treatment were 42% and 11%, respectively (p<0.001).
CONCLUSIONS: IMRT results in significant improvements in the therapeutic ratio among patients treated by radiation therapy for head-and-neck cancer of unknown primary origin.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20421143     DOI: 10.1016/j.ijrobp.2009.11.020

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

Review 1.  [Radiotherapeutic concepts in cancer of unknown primary site].

Authors:  D Krug; J Debus; F Sterzing
Journal:  Radiologe       Date:  2014-02       Impact factor: 0.635

2.  Intensity-modulated radiotherapy vs. parotid-sparing 3D conformal radiotherapy. Effect on outcome and toxicity in locally advanced head and neck cancer.

Authors:  M Lambrecht; D Nevens; S Nuyts
Journal:  Strahlenther Onkol       Date:  2013-01-16       Impact factor: 3.621

3.  Individualized IMRT treatment approach for cervical lymph node metastases of unknown primary.

Authors:  S Janssen; C Glanzmann; G Huber; G Studer
Journal:  Strahlenther Onkol       Date:  2014-02-07       Impact factor: 3.621

4.  Patterns of failure in patients with head and neck carcinoma of unknown primary treated with radiation therapy.

Authors:  John Cuaron; Shyam Rao; Suzanne Wolden; Michael Zelefsky; Karen Schupak; Borys Mychalczak; Nancy Lee
Journal:  Head Neck       Date:  2015-07-06       Impact factor: 3.147

Review 5.  Expanding the therapeutic index of radiation therapy by normal tissue protection.

Authors:  Pierre Montay-Gruel; Lydia Meziani; Chakradhar Yakkala; Marie-Catherine Vozenin
Journal:  Br J Radiol       Date:  2018-07-02       Impact factor: 3.039

6.  Association of Human Papillomavirus Status at Head and Neck Carcinoma Subsites With Overall Survival.

Authors:  Hong Li; Sina J Torabi; Wendell G Yarbrough; Saral Mehra; Heather A Osborn; Benjamin Judson
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-06-01       Impact factor: 6.223

7.  Functional and quality-of-life outcomes of transoral robotic surgery for carcinoma of unknown primary.

Authors:  Kasim Durmus; Hafiz S Patwa; Hamza N Gokozan; Cuneyt Kucur; Theodoros N Teknos; Amit Agrawal; Matthew O Old; Enver Ozer
Journal:  Laryngoscope       Date:  2014-05-02       Impact factor: 3.325

8.  Comparison of survival rates between patients treated with conventional radiotherapy and helical tomotherapy for head and neck cancer.

Authors:  Moonkyoo Kong; Seong Eon Hong; Jinhyun Choi; Youngkyong Kim
Journal:  Radiat Oncol J       Date:  2013-03-31

9.  Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary.

Authors:  Yazan Abu-Shama; Julia Salleron; Florent Carsuzaa; Xu-Shan Sun; Carole Pflumio; Idriss Troussier; Claire Petit; Matthieu Caubet; Arnaud Beddok; Valentin Calugaru; Stephanie Servagi-Vernat; Joël Castelli; Jessica Miroir; Marco Krengli; Paul Giraud; Edouard Romano; Jonathan Khalifa; Mélanie Doré; Nicolas Blanchard; Alexandre Coutte; Charles Dupin; Shakeel Sumodhee; Yungan Tao; Vincent Roth; Lionel Geoffrois; Bruno Toussaint; Duc Trung Nguyen; Jean-Christophe Faivre; Juliette Thariat
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

10.  Late-responding normal tissue cells benefit from high-precision radiotherapy with prolonged fraction delivery times via enhanced autophagy.

Authors:  Qiwei Yao; Rong Zheng; Guozhu Xie; Guixiang Liao; Shasha Du; Chen Ren; Rong Li; Xiaoshan Lin; Daokun Hu; Yawei Yuan
Journal:  Sci Rep       Date:  2015-03-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.